Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Camurus ABCAMRF 81 3-Year EBITDA Growth Rate is 119.10% as of Jun. 2026, which is 699% above its 10-year median of 14.90. GuruFocus rates CAMRF with a GF Score™ of 81/100 and a GF Value™ of $72.91 (Modestly Undervalued). The stock has 2 warning signs investors should review. Among 1,138 Biotechnology companies, Camurus AB ranks better than 99.03% on this metric.
During the past 12 months, Camurus AB's average EBITDA Per Share Growth Rate was -4.20% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 119.10% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 13 years, the highest 3-Year average EBITDA Per Share Growth Rate of Camurus AB was 119.10% per year. The lowest was -44.10% per year. And the median was 14.90% per year.
Camurus AB (OTCPK:CAMRF) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Camurus AB 3-Year EBITDA Growth Rate Related Terms
CAMRF vs VRTX, REGN, ALNY: 3-Year EBITDA Growth Rate Comparison
For the Biotechnology subindustry, Camurus AB's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Camurus AB 3-Year EBITDA Growth Rate vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Camurus AB's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Camurus AB's 3-Year EBITDA Growth Rate falls into.
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 119.10% mean?
Camurus AB (CAMRF) has a 3-Year EBITDA Growth Rate of 119.10% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Camurus AB and its competitors. This is 699% above median its historical median of 14.90. According to the industry distribution chart, Camurus AB ranks #11 out of 1138 companies in the Biotechnology industry, placing it in the top 1%.
Is Camurus AB's 3-Year EBITDA Growth Rate too high?
Camurus AB's current 3-Year EBITDA Growth Rate of 119.10% is 699% above median its 10-year median of 14.90. The Biotechnology industry median 3-Year EBITDA Growth Rate is 14.85. Camurus AB's value of 119.10% is 702% above this industry median. Based on the distribution chart, Camurus AB ranks #11 out of 1138 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Camurus AB has a GF Score™ of 81/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Camurus AB's 3-Year EBITDA Growth Rate compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Camurus AB ranks #11 out of 1138 companies for 3-Year EBITDA Growth Rate. This places Camurus AB in the top 1% of its industry — outperforming the majority of peers. The industry median 3-Year EBITDA Growth Rate is 14.85. Camurus AB's value of 119.10% is 702% above this benchmark. While the company's 10-year median is 14.90 vs. the industry median of 14.85, Camurus AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Biotechnology company?
The median 3-Year EBITDA Growth Rate among Biotechnology companies is 14.85, based on 1,138 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Camurus AB's current 3-Year EBITDA Growth Rate of 119.10% is 702% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Camurus AB and its competitors. For the Biotechnology industry, the median 3-Year EBITDA Growth Rate is 14.85 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Camurus AB's current 3-Year EBITDA Growth Rate is 119.10%, which is 699% above median its own 10-year median of 14.90. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Camurus AB stock overvalued right now?
Based on GuruFocus' analysis, Camurus AB (CAMRF) is currently considered Modestly Undervalued. The stock's GF Value™ is $72.91, compared to a current price of $58.51 — trading 19.8% below its estimated fair value. The current 3-Year EBITDA Growth Rate is 119.10%, which is 699% above median its 10-year median of 14.90 and 702% above the Biotechnology industry median of 14.85. Camurus AB's overall GF Score™ is 81/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Camurus AB (CAMRF), the current 3-Year EBITDA Growth Rate is 119.10% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Camurus AB (CAMRF) Overvalued in 2026?
Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued.
The current stock price of $58.51 is trading 19.8% below its estimated GF Value™ of $72.91.
GuruFocus considers Camurus AB to be Modestly Undervalued.
Key valuation signals for CAMRF:
3-Year EBITDA Growth Rate: 119.10% (699% above median its 10-year median of 14.90)
GF Value™: $72.91 vs. price of $58.51 (19.8% below fair value)
Industry Position: 702% above the Biotechnology median (#11 of 1138)
No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
81GF Score
Get the complete analysis for CAMRF
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CAMRF has been successfully added to your 
